97 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author고성호-
dc.date.accessioned2018-02-26T07:06:22Z-
dc.date.available2018-02-26T07:06:22Z-
dc.date.issued2016-03-
dc.identifier.citationANALYTICAL BIOCHEMISTRY, v. 496, Page. 63-70en_US
dc.identifier.issn0003-2697-
dc.identifier.issn1096-0309-
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0003269715005679?via%3Dihub-
dc.identifier.urihttp://hdl.handle.net/20.500.11754/40635-
dc.description.abstractGlioblastoma is an aggressive malignant brain tumor that starts in the brain or spine and frequently recurs after anticancer treatment. The development of an accurate diagnostic system combined with effective cancer therapy is essential to improve prognosis of glioma patients. Peptides, produced from phage display, are attractive biomolecules for glioma treatment because of their biostability, nontoxicity, and small size. In this study, we employed phage display methodology to screen for peptides that specifically recognize the target PKC delta as a novel biomarker for glioma. The phage library screening yielded four different peptides displayed on phages with a 20- to 200-pM K-d value for the recombinant PKC delta catalytic domain. Among these four phage peptides, we selected one to synthesize and tagged it with fluorescein isothiocyanate (FITC) based on the sequence of the PKC delta-binding phage clone. The synthetic peptide showed a relative binding affinity for antibody and localization in the U373 glioma cell. The kinase activity of PKC delta was inhibited by FITC-labeled peptide with an IC50 of 1.4 mu M in vitro. Consequently, the peptide found in this study might be a promising therapeutic agent against malignant brain tumor. (c) 2016 Elsevier Inc. All rights reserved.en_US
dc.description.sponsorshipThis research was supported by the Converging Research Center Program funded by the Ministry of Science, ICT, and Future Planning (project 2015054348).en_US
dc.language.isoenen_US
dc.publisherACADEMIC PRESS INC ELSEVIER SCIENCEen_US
dc.subjectPKCen_US
dc.subjectBrain gliomaen_US
dc.subjectCancer stem cellen_US
dc.subjectPeptideen_US
dc.subjectPhage displayen_US
dc.titleDesign of a PKC delta-specific small peptide as a theragnostic agent for glioblastomaen_US
dc.typeArticleen_US
dc.relation.volume496-
dc.identifier.doi10.1016/j.ab.2015.12.010-
dc.relation.page63-70-
dc.relation.journalANALYTICAL BIOCHEMISTRY-
dc.contributor.googleauthorCho, Jun-Haeng-
dc.contributor.googleauthorHa, Na-Reum-
dc.contributor.googleauthorKoh, Seong-Ho-
dc.contributor.googleauthorYoon, Moon-Young-
dc.relation.code2016001935-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF MEDICINE[S]-
dc.sector.departmentDEPARTMENT OF MEDICINE-
dc.identifier.pidksh213-
Appears in Collections:
COLLEGE OF MEDICINE[S](의과대학) > MEDICINE(의학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE